Is DocuSign Stock Undervalued?
Digital signature software business DocuSign (NASDAQ:DOCU) has been struggling over…
Sell
23
INTS Quote, Financials, Valuation and Earnings
Last price:
$0.40
Seasonality move
:
-9.18%
Day range:
$0.39 - $0.41
52-week range:
$0.19 - $3.17
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
3.27x
Volume:
742.6K
Avg. volume:
2.9M
1-year change:
-79.33%
Market cap:
$23.6M
Revenue:
--
EPS (TTM):
-$0.63
Analysts' Opinion
-
Consensus RatingIntensity Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $2.92, Intensity Therapeutics, Inc. has an estimated upside of 642.72% from its current price of $0.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.39.
Fair Value
-
According to the consensus of 6 analysts, Intensity Therapeutics, Inc. has 642.72% upside to fair value with a price target of $2.92 per share.
INTS vs. S&P 500
-
Over the past 5 trading days, Intensity Therapeutics, Inc. has underperformed the S&P 500 by -7.28% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Intensity Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Intensity Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Intensity Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Intensity Therapeutics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Intensity Therapeutics, Inc. reported earnings per share of -$0.06.
Enterprise value:
16.6M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-1.75x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$25K
Return On Assets:
-216.62%
Net Income Margin (TTM):
--
Return On Equity:
-380.13%
Return On Invested Capital:
-364.61%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$186.5K | -$24.9K | -$25K | -$7K | -$6K | |
| Operating Income | -$6.5M | -$16.7M | -$12M | -$3.6M | -$2.7M | |
| EBITDA | -$6.3M | -$16.7M | -$12M | -$3.6M | -$2.7M | |
| Diluted EPS | -$0.67 | -$1.18 | -$0.63 | -$0.25 | -$0.06 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $852.8K | $16.6M | $3.8M | $8.2M | |
| Total Assets | -- | $1.2M | $16.8M | $5.2M | $9.6M | |
| Current Liabilities | -- | $5.4M | $724K | $2.3M | $2.3M | |
| Total Liabilities | -- | $5.4M | $904.9K | $2.4M | $2.4M | |
| Total Equity | -- | -$4.2M | $15.9M | $2.8M | $7.2M | |
| Total Debt | -- | -- | $144.9K | $117K | $87K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7.9M | -$13.5M | -$9.5M | -$4M | -$2.4M | |
| Cash From Investing | -$8.8M | $9.2M | -- | $3.1M | -- | |
| Cash From Financing | $22.7M | $411.8K | $13.8M | $413K | $7.2M | |
| Free Cash Flow | -$7.9M | -$13.5M | -$9.5M | -$4M | -$2.4M | |
INTS
Sector
Market Cap
$23.6M
$28.2M
Price % of 52-Week High
12.4%
51.2%
Dividend Yield
0%
0%
Shareholder Yield
-115.7%
-1.54%
1-Year Price Total Return
-79.33%
-18.1%
Beta (5-Year)
--
0.516
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.42
200-day SMA
Sell
Level
$0.61
Bollinger Bands (100)
Buy
Level
0.21 - 0.49
Chaikin Money Flow
Buy
Level
88.2M
20-day SMA
Sell
Level
$0.44
Relative Strength Index (RSI14)
Sell
Level
44.82
ADX Line
Buy
Level
30.92
Williams %R
Buy
Level
-89.0464
50-day SMA
Sell
Level
$0.43
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
1.2B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-22.024)
Sell
CA Score
(Annual)
Level (-6.1905)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (20.9794)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Intensity Therapeutics, Inc. operates as biotechnology company, which develops novel immune-based therapeutic products for cancer treatment. Its product, INT230-6, is a formulation consisting of an amphiphilic cell penetration enhancer molecule combined with cisplatin and vinblastine. The company was founded by Lewis H. Bender in 2012 and is headquartered in Shelton, CT.
Stock Forecast FAQ
In the current month, INTS has received 5 Buy ratings 1 Hold ratings, and 0 Sell ratings. The INTS average analyst price target in the past 3 months is $2.92.
-
Where Will Intensity Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Intensity Therapeutics, Inc. share price will rise to $2.92 per share over the next 12 months.
-
What Do Analysts Say About Intensity Therapeutics, Inc.?
Analysts are divided on their view about Intensity Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Intensity Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Intensity Therapeutics, Inc.'s Price Target?
The price target for Intensity Therapeutics, Inc. over the next 1-year time period is forecast to be $2.92 according to 6 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is INTS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Intensity Therapeutics, Inc. is a Buy. 5 of 6 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INTS?
You can purchase shares of Intensity Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Intensity Therapeutics, Inc. shares.
-
What Is The Intensity Therapeutics, Inc. Share Price Today?
Intensity Therapeutics, Inc. was last trading at $0.40 per share. This represents the most recent stock quote for Intensity Therapeutics, Inc.. Yesterday, Intensity Therapeutics, Inc. closed at $0.39 per share.
-
How To Buy Intensity Therapeutics, Inc. Stock Online?
In order to purchase Intensity Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get INTS Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
INTS
Sector
P/E ratio
--
23.92x
PEG ratio
--
-0.01x
P/B ratio
3.27x
1.83x
Price / LTM sales
--
1.61x
Growth Metrics
INTS
Sector
Revenue growth
--
4.6%
Earnings growth
75.64%
10.88%
Revenue (5-year growth)
--
6.46%
Earnings forecast
-$0.06
-$0.21
Profitability
INTS
Sector
Profitability FY 2024
-$25K
$3.5M
Return on invested capital
-364.61%
-31.84%
Return on assets
-216.62%
-27.96%
Return on equity
-380.13%
-37.63%
Earnings Date
Last Earnings Date
Aug
7
Next Earnings Date
Dec
28
Estimated Next Earnings Date
Mar
29
Balance Sheet
INTS
Sector
Total cash
$7.1M
$26.3M
Short term investments
--
$25.7M
Total assets
$4.8M
$76.9M
Long term debt
$87K
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is SentinelOne Stock Undervalued?
Cybersecurity major SentinelOne (NYSE:S) has struggled over several years, delivering…
Is Broadcom Stock on Sale?
Chip and software maker Broadcom (NASDAQ:AVGO) has been among the…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
72
GLTO alert for Dec 27
Galecto, Inc. [GLTO] is up 16.92% over the past day.
Sell
20
SMX alert for Dec 27
SMX (Security Matters) Plc [SMX] is down 15.76% over the past day.
Sell
11
CDNAF alert for Dec 27
Canadian Tire Corp. Ltd. [CDNAF] is down 10% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
